Clinical features and neuropsychological profile in vascular parkinsonism

Benítez-Rivero, Sonia; Lama, María J.; Huertas‐Fernández, Ismael; Toledo, Paloma Álvarez de; Cáceres‐Redondo, María T.; Martín‐Rodríguez, Juan Francisco; Carrillo, Fátima; Palomar, Francisco J.; Mir, Pablo

doi:10.1016/j.jns.2014.07.046

Cited by 15 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Clinically, severe cognitive decline has been described as a hallmark in patients with so-called vascular parkinsonism. 4,[20][21][22] In agreement, we observed that patients with VP had lower total scores on the Mattis Dementia Rating Scale than healthy controls of similar educational attainment level, reflecting global cognitive impairment. On the Victoria Stroop Task, they specifically had impaired attention and resistance to interference, reduced inhibitory control, and an increased number of errors, findings also concordant with recent studies.…”

Section: Cognitive Impairment In Vascular Parkinsonismsupporting

confidence: 85%

“…On the Victoria Stroop Task, they specifically had impaired attention and resistance to interference, reduced inhibitory control, and an increased number of errors, findings also concordant with recent studies. 3,4 The number of patients receiving levodopa, the dose of levodopa, and the time between last intake and clinical assessment were similar between patients with VP and those with PD. This finding suggests that levodopa medication did not influence cognitive status, as previously reported, [23][24][25] and that it may not account for functional imaging differences in our study.…”

Section: Cognitive Impairment In Vascular Parkinsonismmentioning

confidence: 89%

“…higher cognitive decline with impaired attention and resistance to interference and reduced inhibitory control. 4 Regarding brain morphology, patients with VP are characterized by more frequent basal ganglia lesions [5][6][7] compared with patients with PD and controls. Because attention, resistance to interference, and inhibitory control were related to cingulate cortex function, we hypothesized that basal ganglia functional connectivity with the cingulate cortex could be modified in patients with VP.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Cognitive Impairment and Basal Ganglia Functional Connectivity in Vascular Parkinsonism

Dunet¹,

Deverdun²,

Charroud³

et al. 2016

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

Section: Cognitive Impairment In Vascular Parkinsonismsupporting

confidence: 85%

Section: Cognitive Impairment In Vascular Parkinsonismmentioning

confidence: 89%

mentioning

confidence: 99%

See 1 more Smart Citation

Cognitive Impairment and Basal Ganglia Functional Connectivity in Vascular Parkinsonism

Dunet¹,

Deverdun²,

Charroud³

et al. 2016

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

“…For instance, in the later stages, both diseases present severe non-motor dysfunction, including impaired cognition and depression [ 4 - 6 ]. Compared with patients with PD or healthy controls, VP patients display more profound cognitive declines with impaired attention [ 7 ]. However, risk factors and time to onset for PDD and VP dementia (VPD) vary from patient to patient, reflecting the inter-individual heterogeneity underlying the different pathological substrates of PDD and VPD [ 3 , 8 ].…”

mentioning

confidence: 99%

Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson’s Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage

Zou¹,

Chen²,

Liang³

et al. 2018

Aging and disease

View full text Add to dashboard Cite

Trefoil factor 3 (TFF3), cholinesterase activity (ChE activity) and homocysteine (Hcy) play critical roles in modulating recognition, learning and memory in neurodegenerative diseases, such as Parkinson’s disease dementia (PDD) and vascular parkinsonism with dementia (VPD). However, whether they can be used as reliable predictors to evaluate the severity and progression of PDD and VPD remains largely unknown. Methods: We performed a cross-sectional study that included 92 patients with PDD, 82 patients with VPD and 80 healthy controls. Serum levels of TFF3, ChE activity and Hcy were measured. Several scales were used to rate the severity of PDD and VPD. Receivers operating characteristic (ROC) curves were applied to map the diagnostic accuracy of PDD and VPD patients compared to healthy subjects. Results: Compared with healthy subjects, the serum levels of TFF3 and ChE activity were lower, while Hcy was higher in the PDD and VPD patients. These findings were especially prominent in male patients. The three biomarkers displayed differences between PDD and VPD sub-groups based on genders and UPDRS (III) scores’ distribution. Interestingly, these increased serum Hcy levels were significantly and inversely correlated with decreased TFF3/ChE activity levels. There were significant correlations between TFF3/ChE activity/Hcy levels and PDD/VPD severities, including motor dysfunction, declining cognition and mood/gastrointestinal symptoms. Additionally, ROC curves for the combination of TFF3, ChE activity and Hcy showed potential diagnostic value in discriminating PDD and VPD patients from healthy controls. Conclusions: Our findings suggest that serum TFF3, ChE activity and Hcy levels may underlie the pathophysiological mechanisms of PDD and VPD. As the race to find biomarkers or predictors for these diseases intensifies, a better understanding of the roles of TFF3, ChE activity and Hcy may yield insights into the pathogenesis of PDD and VPD.

show abstract

“…AI-SBR in DAT-SPECT is often used for differentiation between drug-induced or vascular parkinsonism and PD. [38][39][40] In this study, for the discrimination of nPD-nAPD from PD, the accuracy, sensitivity and specificity were as high as 59%, 53% and 88% (P = 0.05). Clinically, initial asymmetry in MM-PD decreases with the progression of the disease, and the value of AI-SBR is reduced gradually.…”

Section: Discussionmentioning

confidence: 52%

The Utility of the Combined Use of <sup>123</sup>I-FP-CIT and <sup>123</sup>I-MIBG Myocardial Scintigraphy in Differentiating Parkinson’s Disease from Other Parkinsonian Syndromes

et al. 2018

View full text Add to dashboard Cite

Background 123 I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy and 123 I-FP-CIT dopamine transporter single photon emission computed tomography (DAT-SPECT) provide specific information that distinguish Parkinson's disease (PD) from parkinsonian syndromes other than PD (non-PD), including atypical parkinsonian disorder (APD) and non-PD other than APD (nPD-nAPD). The purpose of this study was to determine whether combining DAT-SPECT and MIBG myocardial scintigraphy using multiparametric scoring system (MSS) could improve diagnostic test accuracy in discriminating PD from APD or discriminating PD from nPD-nAPD. Methods A total of 52 patients, including 36 PD, eight APD and eight nPD-nAPD, underwent both MIBG myocardial scintigraphy and DAT-SPECT, were evaluated. The heart-to-mediastinum (H/M) ratios (early and delayed), washout-rate (WR), the average (Ave) and asymmetry index (AI) of specific binding ratio (SBR) were calculated. Cutoff values were determined, using ROC analysis, for discriminating PD from APD and for discriminating PD from nPD-nAPD, on five parameters. All cases were scored as either 1 (PD) or 0 (nPD-nAPD or APD) for each parameter according to its threshold in each discrimination. These individual scores were summed for each case, yielding a combined score to obtain a cutoff value for the MSS in each discrimination. Results For discriminating PD from nPD-nAPD, the highest accuracy was 80% at a cutoff value of 19% for the WR and a cut off value of 2 improved diagnostic accuracy to 84% for MSS. For discriminating PD from APD, the highest accuracy was 86% at a cutoff value of 2.8 for the H/M ratio (late) and a cut off value of 2 showed diagnostic accuracy of 86% for MSS. Conclusion A MSS has comparable or better accuracy compared to each parameter of MIBG myocardial scintigraphy and DAT-SPECT in distinguishing PD from nPD-nAPD or distinguishing PD from APD.

show abstract

Clinical features and neuropsychological profile in vascular parkinsonism

Cited by 15 publications

References 27 publications

Cognitive Impairment and Basal Ganglia Functional Connectivity in Vascular Parkinsonism

Cognitive Impairment and Basal Ganglia Functional Connectivity in Vascular Parkinsonism

Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson’s Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage

The Utility of the Combined Use of <sup>123</sup>I-FP-CIT and <sup>123</sup>I-MIBG Myocardial Scintigraphy in Differentiating Parkinson’s Disease from Other Parkinsonian Syndromes

Contact Info

Product

Resources

About